These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31796536)

  • 21. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes.
    Balasubramaniyan N; Luo Y; Sun AQ; Suchy FJ
    J Biol Chem; 2013 May; 288(19):13850-62. PubMed ID: 23546875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
    Wu YC; Roark AA; Bian XL; Wilson VG
    Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.
    Dorval V; Mazzella MJ; Mathews PM; Hay RT; Fraser PE
    Biochem J; 2007 Jun; 404(2):309-16. PubMed ID: 17346237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo characterization of the properties of SUMO1-specific monobodies.
    Berndt A; Wilkinson KA; Heimann MJ; Bishop P; Henley JM
    Biochem J; 2013 Dec; 456(3):385-95. PubMed ID: 24040933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SUMOylation Landscape of Renal Cortical Collecting Duct Cells.
    Wu Q; Aroankins TS; Cheng L; Fenton RA
    J Proteome Res; 2019 Oct; 18(10):3640-3648. PubMed ID: 31502464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3.
    Evdokimov E; Sharma P; Lockett SJ; Lualdi M; Kuehn MR
    J Cell Sci; 2008 Dec; 121(Pt 24):4106-13. PubMed ID: 19033381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction.
    Kim EY; Chen L; Ma Y; Yu W; Chang J; Moskowitz IP; Wang J
    J Mol Cell Cardiol; 2012 Mar; 52(3):638-49. PubMed ID: 22155005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
    Fasci D; Anania VG; Lill JR; Salvesen GS
    Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of small ubiquitin-like modifier substrates with diverse functions using the Xenopus egg extract system.
    Ma L; Aslanian A; Sun H; Jin M; Shi Y; Yates JR; Hunter T
    Mol Cell Proteomics; 2014 Jul; 13(7):1659-75. PubMed ID: 24797264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SENP1 has an important role in lung development and influences the differentiation of alveolar type 2 cells.
    Wan XQ; Cai JY; Zhu Y; Wang QX; Zhu HT; Ju HM; Lu HY
    Int J Mol Med; 2019 Jan; 43(1):371-381. PubMed ID: 30387808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation.
    Liu YY; Kogai T; Schultz JJ; Mody K; Brent GA
    J Biol Chem; 2012 Oct; 287(43):36499-508. PubMed ID: 22930759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of endogenous SUMO1 accepter sites by mass spectrometry.
    Hsiao HH; Meulmeester E; Urlaub H
    Methods Mol Biol; 2012; 893():431-41. PubMed ID: 22665316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUMO1 Modification of Tau in Progressive Supranuclear Palsy.
    Takamura H; Nakayama Y; Ito H; Katayama T; Fraser PE; Matsuzaki S
    Mol Neurobiol; 2022 Jul; 59(7):4419-4435. PubMed ID: 35567706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A role for paralog-specific sumoylation in histone deacetylase 1 stability.
    Citro S; Jaffray E; Hay RT; Seiser C; Chiocca S
    J Mol Cell Biol; 2013 Dec; 5(6):416-27. PubMed ID: 24068740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9.
    Yarahalli Jayaram V; Baggavalli S; Reddy D; Sistla S; Malempati R
    Drug Chem Toxicol; 2020 Nov; 43(6):637-644. PubMed ID: 30426790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ang II Promotes SUMO2/3 Modification of RhoGDI1 Through Aos1 and Uba2 Subunits, and then Regulates RhoGDI1 Stability and Cell Proliferation.
    Qi Y; Guan H; Liang X; Sun J; Yao W
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):769-773. PubMed ID: 33891248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers.
    Rosas-Acosta G; Russell WK; Deyrieux A; Russell DH; Wilson VG
    Mol Cell Proteomics; 2005 Jan; 4(1):56-72. PubMed ID: 15576338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SUMO1 SUMOylates and SENP3 deSUMOylates NLRP3 to orchestrate the inflammasome activation.
    Shao L; Liu Y; Wang W; Li A; Wan P; Liu W; Shereen MA; Liu F; Zhang W; Tan Q; Wu K; Liu Y; Wu J
    FASEB J; 2020 Jan; 34(1):1497-1515. PubMed ID: 31914638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The allosteric effect of the upper half of SENP1 contributes to its substrate selectivity for SUMO1 over SUMO2.
    Shi Y; Yasen M; Wang Z; Du T; Ding Y; Li X; Chai Z; Jie C; Ju G; Ji M
    J Biomol Struct Dyn; 2023; 41(21):12372-12386. PubMed ID: 36656084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates.
    Gocke CB; Yu H; Kang J
    J Biol Chem; 2005 Feb; 280(6):5004-12. PubMed ID: 15561718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.